Abstract
Type 2 diabetes and obesity are among the most prevalent chronic diseases in the United States. Recent research has suggested that these disease states lead to numerous changes in the transcriptome that can be both causal or progressive in nature. Cinnamon has been explored as a potential therapy for type 2 diabetes based on observed decreases in blood glucose in some clinical studies, although its therapeutic benefits are still challenged and its mechanisms of action are still unknown. Aqueous cinnamon extract contains polyphenols, which have been shown to elicit epigenetic changes in several studies. Several key metabolic regulators, thought to be sensitive to epigenetic changes have been identified as players in these disease states. Metabolic regulator FoxO1 is one potential protein sensitive to cinnamon treatment. In addition to metabolic control, FoxO1 has been implemented in numerous other processes including aging, cell death, and lipid localization. Here we present the changes in FoxO1 expression in 3T3‐L1 pre‐adipocytes during early and mid‐stage differentiation both in the presence and absence of cinnamon extract. We have identified increases in FoxO1 expression during mid‐stage differentiation when treated with cinnamon extract. Together with clinical data that demonstrates a phenotype of decreased blood glucose levels in some type 2 diabetic patients when treated with cinnamon, these data suggest the involvement of FoxO1 in the anti‐diabetic mechanisms of cinnamon.Support or Funding InformationOhio Northern University Raabe College of Pharmacy Bower, Bennett and Bennett Research AwardThis abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call